Israel Science and Technology Directory

Alpha DaRT technology utilizes Alpha radiation to treat cancer. DaRT (Diffusing Alpha-emitters Radiation Therapy) treats solid tumors with interstitial radioactive seeds that continually release short-lived alpha-emitting atoms into the tumor.

Motixafortide (BL-8040) cancer therapy platform currently evaluated in a Phase 2a study for the treatment of pancreatic cancer in combination with KEYTRUDA and chemotherapy. Immunotherapy treatment for multiple solid tumors.

Drugs to treat inflammatory diseases and cancer by targeting immune and tumor cell migration via chemokines. BKT104 targeting production of TNF-Alfa. BKT140, a CXCR4 chemokine receptor antagonist for treatment of tumor growth and metastasis.

OncoPro software system for management of complex chemotherapy protocol planning, implementation, analysis and assessment in guidelines-based pediatric adult cancer care in oncology and hematology departments in a range of medical settings.

Development of a drug pipeline for macrophage reprogramming in solid cancers, Sepsis, COVID-19 and other indications. Allocetra for the reprogramming of diseased macrophages in patients with sepsis or COVID-19.

Technology that identifies tumor specific driver mutations based on a functional assay that detects disregulated translocation of mutated signaling proteins to the nucleus. Assay can measure impact of a drug on a specific tumor.

immunotherapy products with unprecedented effects in late stage cancer and HIV positive patients. Therapeutic anti-tumor vaccine developed based on the "Mirror Effect“ which opens a pathway to treating patients with metastatic cancer that have failed available therapy options. Elicits a GVT-like mechanism without the GVHD toxicity.

ExAblate - Magnetic Resonance (MRI) guided Focused Ultrasound (MRgFUS) device that focuses ultrasound energy, to heat and destroy tumor cells inside the body while sparing tissue outside the tumor. Therapy of uterine fibroids.

IZN-6N4 to prevent and treat radiation-induced severe oral mucositis (SOM) in head and neck cancer patients.

Synergo - Medical device for minimally invasive therapeutic outpatient method for ablation of Superficial Transitional Cell Carcinoma of the Bladder (STCCB).

Lead product candidate VB-111 is a targeted anti-cancer biologic agent that is positioned to potentially treat a wide range of solid tumors. Developing proprietary monoclonal antibodies targeting MOSPD2 for immune inflammatory diseases and bi-specific antibodies for cancer.